Compare Stocks: BHC, VRX, APHA, and MJN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APHA Aphria		C$0.00	C$3.93 ▼ C$40.93	C$5.24B	N/A	6.16 million shs	9.61 million shs
BHC Bausch Health Cos	$6.79 -0.6%	$5.66	$4.33 ▼ $8.00	$2.56B	0.37	2.97 million shs	2.16 million shs
MJN Cronos Group	C$12.15 -1.9%	C$12.15	C$1.58 ▼ C$14.83	C$1.73B	N/A	2.07 million shs	1.39 million shs
VRX Valeant Pharmaceuticals International		C$0.00	C$14.01 ▼ C$36.02	C$10.76B	N/A	1.38 million shs	1.23 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APHA Aphria	0.00%	0.00%	0.00%	0.00%	0.00%
BHC Bausch Health Cos	-0.80%	+7.71%	+4.86%	+26.33%	-7.81%
MJN Cronos Group	0.00%	0.00%	0.00%	0.00%	0.00%
VRX Valeant Pharmaceuticals International	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APHA Aphria		C$0.00	C$3.93 ▼ C$40.93	C$5.24B	N/A	6.16 million shs	9.61 million shs
BHC Bausch Health Cos	$6.79 -0.6%	$5.66	$4.33 ▼ $8.00	$2.56B	0.37	2.97 million shs	2.16 million shs
MJN Cronos Group	C$12.15 -1.9%	C$12.15	C$1.58 ▼ C$14.83	C$1.73B	N/A	2.07 million shs	1.39 million shs
VRX Valeant Pharmaceuticals International		C$0.00	C$14.01 ▼ C$36.02	C$10.76B	N/A	1.38 million shs	1.23 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APHA Aphria	0.00%	0.00%	0.00%	0.00%	0.00%
BHC Bausch Health Cos	-0.80%	+7.71%	+4.86%	+26.33%	-7.81%
MJN Cronos Group	0.00%	0.00%	0.00%	0.00%	0.00%
VRX Valeant Pharmaceuticals International	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APHA Aphria	0.00	N/A	N/A	N/A
BHC Bausch Health Cos	1.86	Reduce	$8.00	17.82% Upside
MJN Cronos Group	0.00	N/A	N/A	N/A
VRX Valeant Pharmaceuticals International	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BHC, VRX, APHA, and MJN Analyst Ratings

Date	Company	Brokerage	Action	Rating
8/20/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/31/2026	BHC Bausch Health Cos	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D)
7/24/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/22/2026	BHC Bausch Health Cos	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APHA Aphria	C$611.06M	0.00	N/A	22.40	C$4.76 per share	0.00
BHC Bausch Health Cos	$10.27B	0.25	$7.22 per share	0.94	($2.14) per share	-3.17
MJN Cronos Group	N/A	N/A	N/A	N/A	N/A	N/A
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APHA Aphria	N/A	-C$2.01	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.69	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
MJN Cronos Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest BHC, VRX, APHA, and MJN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APHA Aphria	N/A	N/A	N/A	N/A	N/A
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
MJN Cronos Group	C$1.65	13.58%	N/A	N/A	N/A
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APHA Aphria	59.29	3.37	1.63
BHC Bausch Health Cos	54.68	1.44	1.08
MJN Cronos Group	N/A	N/A	N/A
VRX Valeant Pharmaceuticals International	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APHA Aphria	N/A
BHC Bausch Health Cos	78.65%
MJN Cronos Group	N/A
VRX Valeant Pharmaceuticals International	N/A

Insider Ownership

Company	Insider Ownership
APHA Aphria	N/A
BHC Bausch Health Cos	20.67%
MJN Cronos Group	N/A
VRX Valeant Pharmaceuticals International	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APHA Aphria	1,200	316.80 million	N/A	Not Optionable
BHC Bausch Health Cos	20,300	374.13 million	296.80 million	Optionable
MJN Cronos Group	7,600	142.65 million	N/A	Not Optionable
VRX Valeant Pharmaceuticals International	N/A	349.30 million	N/A	Not Optionable

BHC, VRX, APHA, and MJN Headlines

Recent News About These Companies

Two men charged with kickback scheme at Valeant

June 29, 2026 | uk.finance.yahoo.com

ValueAct slightly ups its position in Valeant Pharmaceuticals

June 26, 2026 | finance.yahoo.com

Valeant Pharma acquires Medicis for US $2.6 billion

May 8, 2025 | pharmaphorum.comP

SCOTUS Passes on Valeant's Challenge to False Claims Act Ruling

October 7, 2024 | news.bloomberglaw.comN

Valeant/Philidor execs convicted of multimillion dollar fraud

October 4, 2024 | pharmaphorum.comP

Valeant Pharmaceuticals International, Inc. v. Silbersher

October 1, 2024 | scotusblog.comS

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

July 28, 2024 | endpts.comE

Kiniksa Pharmaceuticals International PLC Class A

July 26, 2024 | morningstar.comM

Allergan plc Stock Becomes a Buy as It Bottoms Out

April 14, 2024 | aol.comA

Valeant Urges SCOTUS to Clarify Disclosure Rule in Fraud Law

April 11, 2024 | news.bloomberglaw.comN

Valeant Pharmaceuticals International, Inc. (VRX.TO)

February 2, 2024 | finance.yahoo.com

Robbins Umeda LLP Announces an Investigation of the Acquisition of Valeant Pharmaceuticals International by Biovail Corporation

January 4, 2024 | br.advfn.com

Love Him or Hate Him, Ackman Now Runs the Worlds Top Hedge Fund

October 12, 2023 | tradersmagazine.comT

Branded Generics Global Market Report 2023

May 5, 2023 | uk.finance.yahoo.com

Valeant Pharmaceuticals International Stock Hits New 52-Week High (VRX)

March 18, 2023 | thestreet.com

Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Loser

March 10, 2023 | thestreet.com

Valeant Pharmaceuticals International Stock Gaps Up On Today's Open (VRX)

December 26, 2022 | thestreet.com

Valeant Shaves Another Chunk From Its Crushing Debt Load, Shares Continue March Higher

August 26, 2022 | thestreet.com

Despite Woes, Valeant May Be Headed for a Rebound

August 22, 2022 | thestreet.com

JPMorgan Picks 7 Pharmaceutical Stocks to Buy (or Hold) in Wake of Interest Rates Hike

April 30, 2022 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, VRX, APHA, and MJN Company Descriptions

Aphria TSE:APHA

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.

Bausch Health Cos NYSE:BHC

$6.79 -0.04 (-0.59%)

Closing price 09/3/2026 03:58 PM Eastern

Extended Trading

$6.72 -0.07 (-0.97%)

As of 05:07 AM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Cronos Group CVE:MJN

C$12.15 -0.23 (-1.86%)

As of 03/2/2018

Cronos Group Inc, formerly PharmaCan Capital Corp, is a Canada-based cannabis company. The Company operates two Licensed Producers (LPs) regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the ACMPR) and holds a portfolio of investments in other Licensed Producers and ACMPR applicants. Its LPs, Peace Naturals Project Inc. and In The Zone Produce Ltd., are collectively located on over 125 acres of agricultural land. It also holds equity positions in Licensed Producers Whistler Medical Marijuana, Hydropothecary and Abcann Medicinals. Whistler Medical Marijuana is licensed to produce and sell medical marijuana, as well as cultivate cannabis oil. Hydropothecary is licensed to produce medical marijuana. Abcann Medicinals also has license to produce medical marijuana. With interest in five Licensed Producers and two LP applicants, it is focused on building brand portfolio providing patients with personalized care.

Valeant Pharmaceuticals International TSE:VRX

Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHC, VRX, APHA, and MJN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHC, VRX, APHA, and MJN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHC, VRX, APHA, and MJN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, VRX, APHA, and MJN Company Descriptions

Aphria TSE:APHA

Bausch Health Cos NYSE:BHC

Cronos Group CVE:MJN

Valeant Pharmaceuticals International TSE:VRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BHC, VRX, APHA, and MJN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BHC, VRX, APHA, and MJN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BHC, VRX, APHA, and MJN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC, VRX, APHA, and MJN Company Descriptions

Aphria TSE:APHA

Bausch Health Cos NYSE:BHC

Cronos Group CVE:MJN

Valeant Pharmaceuticals International TSE:VRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools